Kyverna Therapeutics (KYTX) EPS (Weighted Average and Diluted) (2023 - 2026)
Kyverna Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.66 for Q1 2026, up 35.92% year-on-year from -$0.49 in Q1 2025, and up 16.46% on a QoQ basis from -$0.79 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.66 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 35.92% year-over-year to -$0.66; the trailing twelve-month figure through Mar 2026 stood at -$3.27 (up 3.25% YoY), and the FY2025 full-year result was -$3.64, down 9.31% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.66, up from -$0.79 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.66 in Q1 2026 and bottomed at -$26.86 in Q4 2023.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.97 (2025), against an average of -$6.99.
- The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) soared 96.79%; it then plunged 44.78% in 2025.
- A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$26.86 in 2023, then jumped by 96.72% to -$0.88 in 2024, then grew by 10.23% to -$0.79 in 2025, then climbed by 16.46% to -$0.66 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.66 (Q1 2026), -$0.79 (Q4 2025), and -$0.85 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | -0.66 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.66 |
| Dec 31, 2025 | -0.79 |
| Sep 30, 2025 | -0.85 |
| Jun 30, 2025 | -0.97 |
| Mar 31, 2025 | -1.03 |
| Dec 31, 2024 | -0.88 |
| Sep 30, 2024 | -0.80 |
| Jun 30, 2024 | -0.67 |
| Mar 31, 2024 | -1.12 |
| Dec 31, 2023 | -26.86 |
| Sep 30, 2023 | -23.27 |
| Jun 30, 2023 | -20.86 |
| Mar 31, 2023 | -12.10 |